Evaluation of idursulfase for the treatment of mucopolysaccharidosis II (Hunter syndrome)

Bibliography

• Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, editor. The metabolic and molecular bases of inherited disease. McGraw-Hill; New York: 2001. p. 3421-52
   Google Scholar
• Bach G, Eisenberg F Jr, Cantz M, Neufeld EF. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci USA 1973;70:2134-8
   PubMed Web of Science ®Google Scholar
• Poorthuis BJ, Wevers RA, Kleijer WJ, The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6
   PubMed Web of Science ®Google Scholar
• Ben Turkia H, Tebib N, Azzouz H, Incidence of mucopolysaccharidoses in Tunisia. Tunis Med 2009;87:782-5
   PubMedGoogle Scholar
• Baehner F, Schmiedeskamp C, Krummenauer F, Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28:1011-7
   PubMed Web of Science ®Google Scholar
• Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000;105:e10
   PubMed Web of Science ®Google Scholar
• Poupetova H, Ledvinova J, Berna L, The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis 2010;33:387-96
   PubMed Web of Science ®Google Scholar
• Pinto R, Caseiro C, Lemos M, Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004;12:87-92
   PubMed Web of Science ®Google Scholar
• Lin HY, Lin SP, Chuang CK, Incidence of the mucopolysaccharidoses in Taiwan. 1984-2004. Am J Med Genet A 2009;149A:960-4
   PubMed Web of Science ®Google Scholar
• Wraith JE, Beck M, Giugliani R, Initial report from the Hunter Outcome Survey. Genet Med 2008;10:508-16
   PubMed Web of Science ®Google Scholar
• Schwartz IV, Ribeiro MG, Mota JG, A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 2007;96:63-70
   Google Scholar
• Martin R, Beck M, Eng C, Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008;121:e377-86
   PubMed Web of Science ®Google Scholar
• Young ID, Harper PS, Archer IM, Newcombe RG. A clinical and genetic study of Hunter's syndrome. 1 Heterogeneity. J Med Genet 1982;19:401-7
   Google Scholar
• Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 1983;25:481-9
   PubMed Web of Science ®Google Scholar
• Jones SA, Almassy Z, Beck M, Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2009;32:534-43
   PubMed Web of Science ®Google Scholar
• Young ID, Harper PS. Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch Dis Child 1982;57:828-36
   PubMed Web of Science ®Google Scholar
• Wraith JE, Scarpa M, Beck M, Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167:267-77
   PubMed Web of Science ®Google Scholar
• Muenzer J, Beck M, Eng CM, Multidisciplinary management of Hunter syndrome. Pediatrics 2009;124:e1228-39
   PubMed Web of Science ®Google Scholar
• Muenzer J, Bodamer O, Burton B, The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr 2011;171(1):181-8
   Google Scholar
• Giugliani R, Federhen A, Rojas MV, Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol 2010;33:589-604
   PubMed Web of Science ®Google Scholar
• Scarpa M, Almassy Z, Beck M, Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 2011;6:72
   PubMed Web of Science ®Google Scholar
• Coppa GV, Gabrielli O, Zampini L, Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two-year follow-up of the first Italian patient and review of the literature. Pediatr Med Chir 1995;17:227-35
   PubMedGoogle Scholar
• McKinnis EJ, Sulzbacher S, Rutledge JC, Bone marrow transplantation in Hunter syndrome. J Pediatr 1996;129:145-8
   PubMed Web of Science ®Google Scholar
• Mullen CA, Thompson JN, Richard LA, Chan KW. Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia. Bone Marrow Transplant 2000;25:1093-7
   PubMed Web of Science ®Google Scholar
• Guffon N, Bertrand Y, Forest I, Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 2009;154:733-7
   PubMed Web of Science ®Google Scholar
• Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 1995;18:413-29
   PubMed Web of Science ®Google Scholar
• Vellodi A, Young E, Cooper A, Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999;22:638-48
   PubMed Web of Science ®Google Scholar
• Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol 2010;47:59-69
   PubMed Web of Science ®Google Scholar
• Green Cross Corporation. Green Cross gains market approval with the world's 2nd orphan drug for Hunter syndrome in South Korea. 12 January 2012. Available from: http://eng.greencross.com/ [Accessed 6 July] 2012
   Google Scholar
• Friso A, Tomanin R, Salvalaio M, Scarpa M. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 2010;159:1082-91
   PubMed Web of Science ®Google Scholar
• Delgadillo V, O'Callaghan M del M, Artuch R, Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 2011;34:1039-44
   PubMed Web of Science ®Google Scholar
• de Ruijter J, Valstar MJ, Narajczyk M, Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012;71:110-20
   PubMed Web of Science ®Google Scholar
• Marucha J, Tylki-Szymanska A, Jakobkiewicz-Banecka J, Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT). Am J Med Genet A 2011;155A:2257-62
   PubMed Web of Science ®Google Scholar
• Muenzer J, Wraith JE, Beck M, A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-73
   PubMed Web of Science ®Google Scholar
• Elaprase® (idursulfase) solution for intravenous infusion [prescribing information]. Shire Human Genetic Therapies, Inc; Cambridge, MA: 2011
   Google Scholar
• Muenzer J, Gucsavas-Calikoglu M, McCandless SE, A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007;90:329-37
   PubMed Web of Science ®Google Scholar
• Muenzer J, Beck M, Eng CM, Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med 2011;13:95-101
   PubMed Web of Science ®Google Scholar
• Schulze-Frenking G, Jones SA, Roberts J, Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 2011;34:203-8
   Web of Science ®Google Scholar
• Muenzer J, Beck M, Giugliani R, Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 2011;13:102-9
   PubMed Web of Science ®Google Scholar
• Vellodi A. Mucopolysaccharidosis type II: guidelines for assessment, monitoring and enzyme replacement therapy (ERT). Available from: http://www.specialisedservices.nhs.uk/library/23/Guidelines_for_Mucopolysaccharidosis_Type_II.pdf [Accessed 2 July] 2012
   Google Scholar
• McGill JJ, Goldblatt J, Peters H, Guidelines for the treatment of mucopolysaccharidosis type II (MPS II) through the Life Saving Drugs Program. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-info/#Idursulfase [Accessed 2 July] 2012
   Google Scholar
• Ontario Public Drug Programs Exceptional Access Program: Elaprase (idursulfase) – Reimbursement Guidelines. Revision 3 (June 2011). Available from: http://www.health.gov.on.ca/english/providers/program/drugs/pdf/elaprase_reimburse.pdf [Accessed July 19] 2012
   Google Scholar
• Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 2005;98:829-36
   PubMed Web of Science ®Google Scholar
• McKie J, Richardson J. The rule of rescue. Soc Sci Med 2003;56:2407-19
   PubMed Web of Science ®Google Scholar
• OnePath® Services. Available from: http://www.elaprase.com/healthcare/about_elaprase/onepath/ [Accessed 2 July 2012]
   Google Scholar
• Tylki-Szymanska A, Jurecka A, Zuber Z, Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr 2012;101:e42-7
   PubMed Web of Science ®Google Scholar
• Giugliani R, Hwu PWL, Tylki-Szymanska A, Whiteman DAH. A multi-center, open-label study evaluating safety and clinical outcomes in young children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. 12th International symposium on MPS and related diseases: 28 June - 1 July, 2012. Noordwijkerhout, the Netherlands; Abstract P100
   Google Scholar
• Lampe C, Bosserhoff A, Burton BK, Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe (neuronopathic) phenotype: an international case series. Final programme and abstracts from the 12th International symposium on MPS and related diseases; 28 June - 1 July, 2012. Noordwijkerhout, the Netherlands; Abstract S08.6
   Google Scholar
• Tuschl K, Gal A, Paschke E, Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 2005;32:270-2
   PubMed Web of Science ®Google Scholar
• Pinto LL, Vieira TA, Giugliani R, Schwartz IV. Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. Orphanet J Rare Dis 2010;5:14
   PubMed Web of Science ®Google Scholar
• Manara R, Rampazzo A, Cananzi M, Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution. J Inherit Metab Dis 2010; DOI: 10.1007/s10545-009-9023-8
   Google Scholar
• Jurecka A, Krumina Z, Zuber Z, Mucopolysaccharidosis type II in females and response to enzyme replacement therapy. Am J Med Genet A 2012;158A:450-4
   PubMed Web of Science ®Google Scholar
• Jurecka A, Żuber A, Opoka-Winiarska V, Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Mol Genet Metab 2012; DOI: 10.1016/j.ymgme.2012.08.013
   Google Scholar
• Felice BR, Wright TL, Boyd RB, Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys. Toxicol Pathol 2011;39:879-92
   PubMed Web of Science ®Google Scholar
• Calias P, Papisov M, Pan J, CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One 2012;7:e30341
   PubMed Web of Science ®Google Scholar
• Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006;20:9-22
   PubMed Web of Science ®Google Scholar
• Clarke LA. The mucopolysaccharidoses: a success of molecular medicine. Expert Rev Mol Med 2008;10:e1
   PubMedGoogle Scholar
• Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446:1030-7
   PubMed Web of Science ®Google Scholar
• Kobialka S, Beuret N, Ben-Tekaya H, Spiess M. Glycosaminoglycan chains affect exocytic and endocytic protein traffic. Traffic 2009;10:1845-55
   Google Scholar
• Settembre C, Arteaga-Solis E, Ballabio A, Karsenty G. Self-eating in skeletal development: implications for lysosomal storage disorders. Autophagy 2009;5:228-9
   PubMed Web of Science ®Google Scholar
• Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, CDC growth charts: United States. Adv Data 2000;1-27
   PubMedGoogle Scholar